EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Mediators between canagliflozin and renoprotection vary depending on patient characteristics: Insights from the CREDENCE trial

Yohei Doi iD, Takayuki Hamano iD, Satoshi Yamaguchi, Yusuke Sakaguchi iD, Jun-Ya Kaimori iD, Yoshitaka Isaka iD

Diabetes, Obesity and Metabolism · 2023

DOI: 10.1111/dom.15191 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2023. Verfasst von Yohei Doi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Osaka University Graduate School of Medicine, Suita, Japan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Kidney Failure, Chronic. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To identify the mediators between canagliflozin and renoprotection in patients with type 2 diabetes at a high risk of end‐stage kidney disease (ESKD).

Methods

In this post hoc analysis of the CREDENCE trial, the effect of canagliflozin on potential mediators (42 biomarkers) at 52 weeks and the association between changes in mediators and renal outcomes were evaluated using mixed‐effects and Cox models, respectively. The renal outcome was a composite of ESKD, serum creatinine doubling or renal death. The percentage of the mediating effect of each significant mediator was calculated based on changes in the hazard ratios of canagliflozin after additional adjustment of the mediator.

Results

Changes in haematocrit, haemoglobin, red blood cell (RBC) count and urinary albumin‐to‐creatinine ratio (UACR) at 52 weeks significantly mediated 47%, 41%, 40% and 29% risk reduction with canagliflozin, respectively. Further, 85% mediation was attributed to the combined effect of haematocrit and UACR. A large variation in mediating effects by haematocrit change existed among the subgroups, ranging from 17% in those patients with a UACR of more than 3000 mg/g to 63% in patients with a UACR of 3000 mg/g or less. In the subgroups with a UACR of more than 3000 mg/g, UACR change was the highest mediating factor (37%), driven by the strong association between UACR decline and renal risk reduction.

Conclusions

The renoprotective effects of canagliflozin in patients at a high risk of ESKD can be significantly explained by changes in RBC variables and UACR. The complementary mediating effects of RBC variables and UACR may support the renoprotective effect of canagliflozin in different patient groups.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsKidney Failure, ChronicHumansCanagliflozinTreatment OutcomeKidneyGlomerular Filtration RateAlbuminuria

Stichwörter der Autor:innen

canagliflozinclinical trialdiabetic nephropathydrug mechanismtype 2 diabetes

Substanzen

CanagliflozinSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Department of Nephrology, Osaka University Graduate School of Medicine, Suita, Japan.
  • Department of Cardiology, Pulmonology, Hypertension & Nephrology, Ehime University Graduate School of Medicine, Toon, Japan.
  • Department of Nephrology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
  • Department of Nephrology, Japan Community Health Care Organization Osaka Hospital, Osaka, Japan.

ORCID-Profile: Yohei Doi, Takayuki Hamano, Yusuke Sakaguchi, Jun-Ya Kaimori, Yoshitaka Isaka

Zitieren

APA

Doi, Y., Hamano, T., Yamaguchi, S., Sakaguchi, Y., Kaimori, J. Y., & Isaka, Y. (2023). Mediators between canagliflozin and renoprotection vary depending on patient characteristics: Insights from the CREDENCE trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15191

Vancouver

Doi Y, Hamano T, Yamaguchi S, Sakaguchi Y, Kaimori JY, Isaka Y. Mediators between canagliflozin and renoprotection vary depending on patient characteristics: Insights from the CREDENCE trial. Diabetes, Obesity and Metabolism. 2023. doi:10.1111/dom.15191

BibTeX
@article{Doi2023,
  author = {Doi, Yohei and Hamano, Takayuki and Yamaguchi, Satoshi and Sakaguchi, Yusuke and Kaimori, Jun-Ya and Isaka, Yoshitaka},
  title = {Mediators between canagliflozin and renoprotection vary depending on patient characteristics: Insights from the CREDENCE trial},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2023},
  doi = {10.1111/dom.15191}
}
Kostenlos starten →